{"title":"A Comprehensive Retrospective Analysis of Trends and Strategic Implications of 505(b)(2) Approvals (2019-2023).","authors":"Ramesh Joga, Kailas Vijay Gadekar, Kajal Gandhi, M Sowndharya, Sonali Waikar, Rajeev Singh Raghuvanshi, Saurabh Srivastava","doi":"10.1007/s43441-025-00775-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The 505(b)(2) pathway, established by the USFDA, enables faster approval of new drug applications (NDAs) by allowing partial reliance on existing clinical data. This regulatory mechanism fosters innovation by encouraging new formulations, combinations, and delivery systems, accelerating the availability of advanced therapeutics.</p><p><strong>Objective: </strong>This study provides a comprehensive analysis of 505(b)(2) NDA approvals from 2019 to 2023, with an emphasis on trends, major players, therapeutic targets, and dosage form diversity. Furthermore, the impact of regulatory exclusivity strategies on market dynamics and drug pricing is explored.</p><p><strong>Methods: </strong>Approval data was gathered from the USFDA database and further classified by reformulation type, therapeutic area, primary players, and dosage form. The study also analyzed the therapeutic equivalence codes and the influence of non-patent exclusivity strategies on market competition to identify trends and the prevalence of product types across therapeutic categories.</p><p><strong>Results: </strong>Our findings reveal a strong presence of reformulations, with new dosage forms (Type 3) and new formulations or other differences (Type 5) accounting for a substantial portion of approvals. Cancer (16.7%), CNS disorders (16.2%), and anti-infective treatments emerged as key therapeutic areas. Teva Pharmaceuticals USA Inc. was the leading entity by approval count. Parenteral dosage forms dominated at 40.3%, followed by tablets at 20.6%. Exclusivity strategies, notably three year's new clinical investigation exclusivity, impacted drug pricing and competitive positioning.</p><p><strong>Conclusion: </strong>The 505(b)(2) pathway proves instrumental in advancing pharmaceutical innovation and expediting access to therapies targeting unmet needs. These insights offer value for regulatory professionals, drug developers, and policymakers in optimizing development and market strategies to enhance drug accessibility. Companies must remain vigilant and proactive in anticipating potential blocking exclusivities to secure successful approvals.</p>","PeriodicalId":23084,"journal":{"name":"Therapeutic innovation & regulatory science","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic innovation & regulatory science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43441-025-00775-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL INFORMATICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The 505(b)(2) pathway, established by the USFDA, enables faster approval of new drug applications (NDAs) by allowing partial reliance on existing clinical data. This regulatory mechanism fosters innovation by encouraging new formulations, combinations, and delivery systems, accelerating the availability of advanced therapeutics.
Objective: This study provides a comprehensive analysis of 505(b)(2) NDA approvals from 2019 to 2023, with an emphasis on trends, major players, therapeutic targets, and dosage form diversity. Furthermore, the impact of regulatory exclusivity strategies on market dynamics and drug pricing is explored.
Methods: Approval data was gathered from the USFDA database and further classified by reformulation type, therapeutic area, primary players, and dosage form. The study also analyzed the therapeutic equivalence codes and the influence of non-patent exclusivity strategies on market competition to identify trends and the prevalence of product types across therapeutic categories.
Results: Our findings reveal a strong presence of reformulations, with new dosage forms (Type 3) and new formulations or other differences (Type 5) accounting for a substantial portion of approvals. Cancer (16.7%), CNS disorders (16.2%), and anti-infective treatments emerged as key therapeutic areas. Teva Pharmaceuticals USA Inc. was the leading entity by approval count. Parenteral dosage forms dominated at 40.3%, followed by tablets at 20.6%. Exclusivity strategies, notably three year's new clinical investigation exclusivity, impacted drug pricing and competitive positioning.
Conclusion: The 505(b)(2) pathway proves instrumental in advancing pharmaceutical innovation and expediting access to therapies targeting unmet needs. These insights offer value for regulatory professionals, drug developers, and policymakers in optimizing development and market strategies to enhance drug accessibility. Companies must remain vigilant and proactive in anticipating potential blocking exclusivities to secure successful approvals.
期刊介绍：
Therapeutic Innovation & Regulatory Science (TIRS) is the official scientific journal of DIA that strives to advance medical product discovery, development, regulation, and use through the publication of peer-reviewed original and review articles, commentaries, and letters to the editor across the spectrum of converting biomedical science into practical solutions to advance human health.
The focus areas of the journal are as follows:
Biostatistics
Clinical Trials
Product Development and Innovation
Global Perspectives
Policy
Regulatory Science
Product Safety
Special Populations
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
